Tybost is a medicine for treating adults and adolescents from 12 years of age (and over a certain weight) who are infected with HIV-1, a virus that causes acquired immune deficiency syndrome (AIDS). Tybost does not treat HIV directly but is given to boost the effects of atazanavir or darunavir, which are used with other standard medicines to treat HIV-1. It contains the active substance cobicistat.
Therapeutic Indication
### Therapeutic indication Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older: - weighing at least 35 kg co?administered with atazanavir or - weighing at least 40 kg co?administered with darunavir.
Therapeutic Area (MeSH)
ATC Code
V03AX03
ATC Item
cobicistat
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| cobicistat | N/A | 可比司他 |
EMA Name
Tybost
Medicine Name
Tybost
Aliases
N/A